||WAY-252623 (LXR-623) is an orally bioavailable and highly specifical synthetic modulator of LXR.
||SR9243, an LXR inverse agonist, can induce LXR-corepressor interaction; shows anticancer activity and selectively targets the lipogenesis and Warburg effect.
||BMS-779788 is an LXRα/β partial agonist (IC50: 68/14 nM).
||GW3965 HCl is an effective and specific LXR agonist for hLXRα/β (EC50: 190/30 nM).
||T0901317 is a potent and selective agonist for both LXR and FXR, with EC50 of ~50 nM and 5 μM, respectively; it inhibits nuclear factor/κB (NF/κB).
||AZ876 is a potent, highly selective LXR agonist with Ki/EC50 of 7/6 nM and 11/73 nM for hLXRα and hLXRβ respectively.
||RGX-104 is a liver X receptor (LXR) agonist with potential immunomodulating and antineoplastic activities. It modulates innate immunity via transcriptional activation of the ApoE g
||Gymnemagenin is a potent and selective antagonist for the β isoform of LXR, it has antihyperglycemic activity.